Chat on WhatsApp
← View all blogs
PCOS and Weight Loss in Ireland: Can GLP-1 Medications Help?

22 Jul 2026

PCOS and Weight Loss in Ireland: Can GLP-1 Medications Help?

PCOSpolycystic ovary syndromeweight lossIrelandMounjaroWegovyGLP-1insulin resistance

All medical information is reviewed by our clinical partners at MedicOnline.

Dr. Jahan Khan

Dr. Jahan Khan, CMO @ MedicOnline

IMC 409788

If you have PCOS and have been told to "just lose weight," you already know how unhelpful that advice is. You have probably tried. Repeatedly. And you have probably watched the weight come back every time, or felt like your body was working against you in a way that nobody around you quite understood.

It was not a lack of effort. PCOS fundamentally changes how your body stores fat, processes insulin, and responds to calorie restriction. The standard "eat less, move more" approach was never designed for a body that is dealing with those hormonal disruptions.

The question many women with PCOS in Ireland are now asking is whether the new generation of weight loss medications - Mounjaro and Wegovy - could make a difference. The short answer is that the evidence is growing, and for women who meet the clinical criteria, these treatments may offer real help. But there are important details to understand first.

Why PCOS Makes Weight Loss So Difficult

Polycystic ovary syndrome affects roughly 1 in 10 women of reproductive age in Ireland. It is a hormonal condition, and one of its most common and most frustrating features is weight gain that resists conventional dieting.

There are specific biological reasons for this, and understanding them matters because it changes how you think about treatment.

Insulin resistance

Up to 70% of women with PCOS have some degree of insulin resistance, regardless of their weight. When your cells do not respond properly to insulin, your body produces more of it to compensate. Elevated insulin promotes fat storage - particularly around the abdomen - and makes it significantly harder to burn stored fat through diet alone.

Hormonal appetite disruption

The hormonal imbalances in PCOS can affect the signals that regulate hunger and fullness. Many women with PCOS report feeling genuinely hungrier than their peers, experiencing stronger cravings (particularly for carbohydrates), and feeling less satisfied after meals. This is not a willpower problem. It is a hormonal one.

Metabolic adaptation

When women with PCOS restrict calories, their bodies can respond more aggressively than average by slowing metabolism and increasing hunger signals. This is the "set point" defence that makes weight regain so common after dieting, and it tends to be more pronounced in women with insulin resistance.

The vicious cycle

Weight gain worsens insulin resistance, which worsens the hormonal imbalance, which makes further weight gain more likely. Breaking out of this cycle through diet and exercise alone is possible for some women, but for many it is extraordinarily difficult without additional support.

For a broader look at why traditional diets fail for many people, see our post on the science of metabolic weight loss.

What the Evidence Says About GLP-1 Medications and PCOS

GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro) are not specifically licensed for PCOS. They are licensed for weight management in adults who meet BMI criteria. However, there is a growing body of clinical evidence suggesting that these medications may be particularly beneficial for women with PCOS, for several reasons.

  • Improved insulin sensitivity: GLP-1 medications improve how your body responds to insulin. For women with PCOS-related insulin resistance, this addresses one of the root drivers of weight gain, not just the symptom. A 2024 meta-analysis published in Diabetes, Obesity and Metabolism found that GLP-1 receptor agonists significantly improved insulin sensitivity markers in women with PCOS compared to placebo.

  • Meaningful weight loss: The STEP and SURMOUNT clinical trials that led to Wegovy and Mounjaro's approval included participants with insulin resistance and prediabetes - conditions that overlap heavily with PCOS. The weight loss results in these subgroups were consistent with the broader trial populations.

  • Potential hormonal benefits: Some research suggests that the weight loss achieved through GLP-1 medications can improve androgen levels, menstrual regularity, and fertility outcomes in women with PCOS. These are secondary benefits driven by the weight loss itself rather than a direct effect of the medication, but they are clinically meaningful for many women.

  • Reduced cravings: One of the most commonly reported effects of GLP-1 medications is the quieting of "food noise" - the constant, intrusive thoughts about food that many women with PCOS experience as a result of their hormonal profile. For some patients, this is the single most life-changing aspect of treatment.

It is important to be clear: these medications are not a PCOS treatment. They are a weight management treatment that may be especially helpful for women whose PCOS makes conventional weight loss approaches ineffective. The decision to prescribe is always based on a full clinical assessment of your individual health profile.

Do You Qualify for Treatment?

The eligibility criteria for Mounjaro and Wegovy in Ireland are the same whether or not you have PCOS:

  • A BMI of 30 or above, or
  • A BMI of 27 or above with at least one weight-related health condition

Here is where PCOS becomes directly relevant. Many of the qualifying comorbidities overlap with conditions commonly seen in PCOS:

  • Insulin resistance or prediabetes
  • Type 2 diabetes
  • High blood pressure
  • High cholesterol or dyslipidaemia
  • Obstructive sleep apnoea

If you have PCOS and a BMI of 27 or above, there is a reasonable chance you meet the eligibility criteria through one of these associated conditions. Your doctor will assess this during your consultation.

For full details on the eligibility process, see our guides to Mounjaro eligibility and Wegovy eligibility in Ireland.

Not sure if you qualify? You can check your eligibility online in under 4 minutes. Our doctors assess your full health profile, including PCOS-related conditions.

What to Discuss with Your Doctor

If you have PCOS and are considering GLP-1 treatment, there are a few things worth raising during your consultation:

Your full PCOS history: Including when you were diagnosed, what treatments you have tried (metformin, oral contraceptives, lifestyle interventions), and how your weight has responded to previous approaches. This context helps your doctor understand what has and has not worked.

Current medications: If you are taking metformin for insulin resistance, your doctor will factor this into the treatment plan. Metformin and GLP-1 medications can be used together, but the combination needs to be managed.

Fertility considerations: If you are planning to become pregnant, this affects the treatment timeline. GLP-1 medications are contraindicated during pregnancy, and treatment should be stopped at least two months before trying to conceive. However, the weight loss achieved before conception can significantly improve fertility outcomes for women with PCOS.

Realistic expectations: GLP-1 medications are not a cure for PCOS. They can help with weight management, which in turn can improve many PCOS symptoms. But the underlying hormonal condition will still need ongoing management.

Why This Matters Beyond the Scale

For women with PCOS, weight loss is rarely just about appearance. Even a 5-10% reduction in body weight has been shown to:

  • Improve insulin sensitivity
  • Restore more regular menstrual cycles
  • Reduce androgen levels (which can improve acne and excess hair growth)
  • Improve fertility outcomes
  • Lower the long-term risk of type 2 diabetes and cardiovascular disease

The clinical trials behind Mounjaro and Wegovy showed average weight loss well beyond that 5-10% threshold, which is why there is growing clinical interest in their use for women with PCOS who meet the prescribing criteria.

Getting Started

If you have PCOS and have been struggling with weight management, you are not failing. Your biology has been making it harder than it should be. The newer generation of weight loss medications may offer a way to work with your body rather than against it.

Treatment is always subject to a full clinical assessment by an IMC-registered doctor, and a prescription is not guaranteed. But if you meet the criteria, having a doctor who understands both PCOS and medical weight management can make a real difference to your outcomes.

At Bua, our programme includes ongoing dietitian support alongside medical treatment - which matters for PCOS patients, who often benefit from specific dietary approaches (such as lower glycaemic-load eating patterns) that complement the medication.

Trustpilot
Check your eligibility now

Related Reading

References

Related Blogs

Who Qualifies for Mounjaro in Ireland?

Who Qualifies for Mounjaro in Ireland?

An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.

Read
What weight loss injections are available in Ireland?

What weight loss injections are available in Ireland?

A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026

Read
Who can't take Mounjaro? Understanding the contraindications

Who can't take Mounjaro? Understanding the contraindications

A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.

Read
PCOS and Weight Loss in Ireland: Can GLP-1 Medications Help?